Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N. Engl. J. Med.

Title: The New England journal of medicine

Publisher: New England Journal of Medicine (NEJM/MMS)

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Jun 09 2016

Volume: 374

Issue: 23

Affiliations

[1 ] From the National Heart and Lung Institute, Imperial College London, London (J.A.W.), and the Centre for Respiratory Medicine and Allergy, University of Manchester and University Hospital South Manchester NHS Foundation Trust, Manchester (J.V.) - all in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (D.B., R.T.A., C.T., R.F.); Asthma and Airway Centre, University Health Network and University of Toronto, Toronto (K.R.C.); Service de Pneumologie Assistance Publique-Hôpitaux de Paris, University Paris Descartes (EA2511), Paris (N.R.); Novartis Pharma AG, Basel, Switzerland (F.P.); and the Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany (C.F.V.).

Article

DOI: 10.1056/NEJMoa1516385

PubMed ID: 27181606

SO-VID: 190615fb-bca9-49dc-9b21-5216621d8048

History

Data availability:

Comments

Comment on this article

scite_

Cited by 300

See all cited by